TY - JOUR

T1 - HPV-prevalence in elderly women in Denmark

AU - Andersen, Berit

AU - Christensen, Birgitte Schütt

AU - Christensen, Jette

AU - Ejersbo, Dorthe

AU - Heje, Hanne Nørgaard

AU - Jochumsen, Kirsten Marie

AU - Johansen, Tonje

AU - Larsen, Lise Grupe

AU - Lynge, Elsebeth

AU - Serizawa, Reza

AU - Viborg, Petra Hall

AU - Waldstrøm, Marianne

PY - 2019

Y1 - 2019

N2 - Aim: In countries like Denmark, cervical cancer incidence is at present relatively high in elderly women, while routine screening stops at age 65 years. On this background, all women aged 69 and above were invited to human papillomavirus (HPV)-screening in Denmark in 2017. Methods: Women were identified from the Central Population Register and personally invited by digital or ordinary mail to have a screening sample taken by their general practitioner. In four regions, samples were tested for high risk (HPV) with the cobas 4800® HPV-assay, and in the last region with the BD Onclarity® HPV-assay. Participation rate, prevalence of high risk HPV, and proportion of positive samples with HPV16, HPV18, and other high risk HPV-types were tabulated by 5-year age-groups. Results: 455,612 women were invited, and 30.2% (95 confidence interval (CI) 30.0–30.3) participated. Average age of participants was 74.6 years. Overall, 4.3% (95% CI 4.1–4.4) of participants were HPV-positive, of whom 24% had HPV 16/18. HPV-prevalence decreased slightly from 4.5% in women aged 69–73 years to 3.1% in women aged 84–88 years, but was 5.2% in the very small group of participants aged 89+ years. Conclusion: Invitation to HPV-screening was well received by elderly women. The HPV-prevalence decreased slightly with increasing age. No rebound of HPV-prevalence after menopause was found when our data were combined with previously published Danish data from younger women. The presently relatively high cervical cancer incidence in elderly women was not reflected in the HPV-prevalence.

AB - Aim: In countries like Denmark, cervical cancer incidence is at present relatively high in elderly women, while routine screening stops at age 65 years. On this background, all women aged 69 and above were invited to human papillomavirus (HPV)-screening in Denmark in 2017. Methods: Women were identified from the Central Population Register and personally invited by digital or ordinary mail to have a screening sample taken by their general practitioner. In four regions, samples were tested for high risk (HPV) with the cobas 4800® HPV-assay, and in the last region with the BD Onclarity® HPV-assay. Participation rate, prevalence of high risk HPV, and proportion of positive samples with HPV16, HPV18, and other high risk HPV-types were tabulated by 5-year age-groups. Results: 455,612 women were invited, and 30.2% (95 confidence interval (CI) 30.0–30.3) participated. Average age of participants was 74.6 years. Overall, 4.3% (95% CI 4.1–4.4) of participants were HPV-positive, of whom 24% had HPV 16/18. HPV-prevalence decreased slightly from 4.5% in women aged 69–73 years to 3.1% in women aged 84–88 years, but was 5.2% in the very small group of participants aged 89+ years. Conclusion: Invitation to HPV-screening was well received by elderly women. The HPV-prevalence decreased slightly with increasing age. No rebound of HPV-prevalence after menopause was found when our data were combined with previously published Danish data from younger women. The presently relatively high cervical cancer incidence in elderly women was not reflected in the HPV-prevalence.

KW - Age

KW - Cervical cancer

KW - Human papillomavirus

KW - Prevalence

KW - Screening

U2 - 10.1016/j.ygyno.2019.04.680

DO - 10.1016/j.ygyno.2019.04.680

M3 - Journal article

C2 - 31088688

AN - SCOPUS:85065447780

VL - 154

SP - 118

EP - 123

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -